Skip to main content

Table 5 Cost-effectiveness analysis results according to PFS and OS for each treatment group. Amounts are presented in MXN pesos

From: Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations

TKI Mean total cost Incremental Cost Effectiveness Incremental Effectiveness ICER
Progression Free Survival (PFS)
 Gefitinib $161,800   8.18   Lowest cost
 Erlotinib $215,700 $53,900 6.7 −1.48 Dominated by gefitinib
 Afatinib $348,200 $186,400 9.46 1.28 $145,625.00 vs gefitinib
Overall Survival (OS)
 Gefitinib $161,800   27.1   Lowest cost
 Erlotinib $215,700 $53,900 21.7 −5.4 Dominated by gefitinib
 Afatinib $348,200 $186,400 37.1 10 $18,640.00 vs gefitinib